Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Kevin J Harrington"'
Autor:
Keith C. Bible, Irene Brana, Mollie Leoni, Stephan Hackenberg, Jessica Bauman, Pol Specenier, Jérôme Fayette, Catherine Rose Scholz, Binaifer Balsara, Maria Jose Flor, Bridget Martell, Alan L. Ho, Robert I. Haddad, Valentina Boni, Caroline Even, Sjoukje F. Oosting, Sung-Bae Kim, Kevin J. Harrington, Nabil F. Saba, Francis P. Worden, Antonio Gualberto, Lisa Licitra, Ioanna Nixon, Deborah J. Wong, Myung-Ju Ahn
Publikováno v:
Journal of clinical oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(17):JCO2002903, 1856-1864. AMER SOC CLINICAL ONCOLOGY
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(17):JCO2002903, 1856-1864. AMER SOC CLINICAL ONCOLOGY
PURPOSEMutations in the HRAS (m HRAS) proto-oncogene occur in 4%-8% of patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Tipifarnib is a farnesyltransferase inhibitor that disrupts HRAS function. We evalua
Autor:
M Dvorkin, Jean Bourhis, Antonio Rueda, Amanda Psyrri, József Lövey, Robert L. Ferris, Holger Thurm, Steven De Beukelaer, Mohammad Abdul Razaq, Kevin J. Harrington, Chaosu Hu, Lara Dunn, Jin-Ching Lin, Ezra E.W. Cohen, Makoto Tahara, Robert I. Haddad, Nancy Y. Lee, Dmitri Pavlov, Peter Mu Hsin Chang, Maria Margarida Teixeira, Jerome Chamois
Publikováno v:
The Lancet Oncology. 22:450-462
Summary Background Chemoradiotherapy is the standard of care for unresected locally advanced squamous cell carcinoma of the head and neck. We aimed to assess if addition of avelumab (anti-PD-L1) to chemoradiotherapy could improve treatment outcomes f
Autor:
Timothy Kottke, Laura Evgin, Christopher B. Driscoll, Phonphimon Wongthida, Jill Thompson, Brady Zell, Adel Samson, Jason M. Tonne, Amanda L. Huff, Lewis R. Roberts, Elizabeth Ilett, Peter Selby, Alan Melcher, Kevin J. Harrington, Jacob van Vloten, Mitesh J. Borad, Hardev Pandha, Matthew Schuelke, Richard G. Vile, Mark A. McNiven, Victoria A. Jennings, Jose S. Pulido
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Nature Communications
Nature Communications
In our clinical trials of oncolytic vesicular stomatitis virus expressing interferon beta (VSV-IFNβ), several patients achieved initial responses followed by aggressive relapse. We show here that VSV-IFNβ-escape tumors predictably express a point-m
Autor:
M. Denyer, Nicola E. Annels, Guy Simpson, Kevin J. Harrington, Richard G. Vile, Mehreen Arif, Hardev Pandha, Alan Melcher, Matthew C. Coffey
Publikováno v:
Molecular Therapy Oncolytics
Molecular Therapy: Oncolytics, Vol 20, Iss, Pp 434-446 (2021)
Molecular Therapy: Oncolytics, Vol 20, Iss, Pp 434-446 (2021)
Prostate cancers are considered “cold” tumors characterized by minimal T cell infiltrates, absence of a type I interferon (IFN) signature, and the presence of immunosuppressive cells. This non-inflamed phenotype is likely responsible for the lack
Publikováno v:
Clinical Cancer Research. 27:689-703
Therapeutic cancer vaccines, an exciting development in cancer immunotherapy, share the goal of creating and amplifying tumor-specific T-cell responses, but significant obstacles still remain to their success. Here, we briefly outline the principles
Autor:
Joan N. Kyula, Gabriella Baker, David Mansfield, Matthew Chiu, Anna Wilkins, Kevin J. Harrington, Eva Crespo-Rodriguez, Edward Armstrong, Alan Melcher, Martin McLaughlin, Fiona McDonald, Vicki Jennings, Victoria Roulstone, Shane Foo, Malin Pedersen, Galabina Bozhanova, Lorna Grove, Emmanuel C Patin
Publikováno v:
Expert Opinion on Biological Therapy. 20:635-652
Introduction: Immune checkpoint inhibitors (ICI) have dramatically improved the outcome for cancer patients across multiple tumor types. However the response rates to ICI monotherapy remain relativ...
Publikováno v:
Nature Immunology. 21:120-134
Therapeutic irradiation of the tumor microenvironment causes differential activation of pro-survival and pro-death pathways in malignant, stromal, endothelial and immune cells, hence causing a profound cellular and biological reconfiguration via mult
Autor:
Bas W. Raaymakers, Marcel Verheij, Bruce D. Minsky, Jan J W Lagendijk, Arjun Sahgal, Parag J. Parikh, William A. Hall, Kevin J. Harrington, Ananya Choudhury, Robert J H A Tersteeg, Clifton D. Fuller, Uulke A. van der Heide, Eric S. Paulson, Michael F. Bassetti, Laura A. Dawson, Percy Lee, David A. Jaffray, Beth Erickson, Clifford G. Robinson, X. Allen Li, Christopher J. Schultz
Publikováno v:
Eur J Cancer
European Journal of Cancer, 122, pp. 42-52
European Journal of Cancer, 122, 42-52
European Journal of Cancer, 122, 42. Elsevier Limited
Hall, W A, Paulson, E S, Heide, U A V D, Fuller, C D, Raaymakers, B W, Lagendijk, J J W, Li, X A, Jaffray, D A, Dawson, L A, Erickson, B, Verheij, M, Harrington, K J, Sahgal, A, Lee, P, Parikh, P J, Bassetti, M F, Robinson, C G, Choudhury, A, Tersteeg, J H A & Schultz, C J 2019, ' The Transformation Of Radiation Oncology Using Real-Time Magnetic Resonance Guidance : A Review ', European Journal of Cancer . https://doi.org/10.1016/j.ejca.2019.07.021
European Journal of Cancer, 122, pp. 42-52
European Journal of Cancer, 122, 42-52
European Journal of Cancer, 122, 42. Elsevier Limited
Hall, W A, Paulson, E S, Heide, U A V D, Fuller, C D, Raaymakers, B W, Lagendijk, J J W, Li, X A, Jaffray, D A, Dawson, L A, Erickson, B, Verheij, M, Harrington, K J, Sahgal, A, Lee, P, Parikh, P J, Bassetti, M F, Robinson, C G, Choudhury, A, Tersteeg, J H A & Schultz, C J 2019, ' The Transformation Of Radiation Oncology Using Real-Time Magnetic Resonance Guidance : A Review ', European Journal of Cancer . https://doi.org/10.1016/j.ejca.2019.07.021
Radiation therapy (RT) is an essential component of effective cancer care and is used across nearly all cancer types. The delivery of RT is becoming more precise through rapid advances in both computing and imaging. The direct integration of magnetic
Autor:
Jeffery S. Russell, Shanmugasundaram Ramkumar, Everett E. Vokes, Robert L. Ferris, Makoto Tahara, Maura L. Gillison, Lisa Licitra, Mark Lynch, Robert I. Haddad, Joël Guigay, Caroline Even, Nabil F. Saba, Kevin J. Harrington, Fernando Concha-Benavente, Jérôme Fayette, Li Li, Peter Brossart, George R. Blumenschein, A. Dimitrios Colevas
Publikováno v:
Clin Cancer Res
Purpose: Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or metastatic (R/M) squamous cell carcinoma
Autor:
Richard G. Vile, Victoria Roulstone, Kevin J. Harrington, Hardev Pandha, Sophia N. Karagiannis, C L White, Robert J. Harris, Johann S. de Bono, Alan Melcher, Katie Twigger, David Mansfield, James Spicer
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
BackgroundOncolytic reovirus therapy for cancer induces a typical antiviral response to this RNA virus, including neutralizing antibodies. Concomitant treatment with cytotoxic chemotherapies has been hypothesized to improve the therapeutic potential